{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:29:40Z","timestamp":1768408180071,"version":"3.49.0"},"reference-count":49,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.5551\/jat.cr002","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T22:15:35Z","timestamp":1517868935000},"page":"539-553","source":"Crossref","is-referenced-by-count":76,"title":["Guidance for Pediatric Familial Hypercholesterolemia 2017"],"prefix":"10.5551","volume":"25","author":[{"given":"Mariko","family":"Harada-Shiba","sequence":"first","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Child Health and Welfare (Pediatrics), Faculty of Medicine, University of the Ryukyu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ohtake","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Saitama Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nohara","sequence":"additional","affiliation":[{"name":"Kanazawa University Health Service Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Community Medicine & Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Rinku General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[{"name":"Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","unstructured":"1) Goldstein JL, Hobbs HH, Brown MS: Familial hypercholesterolemia, 8th edn, vol. 2. McGraw-Hill: New York, 2001; 2863-2913"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, Nakanishi C, Mori M, Yamagishi M, Inazu A, Koizumi J, Hokuriku FH Study Group: Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011; 214: 404-407","DOI":"10.1016\/j.atherosclerosis.2010.11.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) sclerosis, 2011; 214: 404-407 3) Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS: Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA, 2003; 290: 2271-2276","DOI":"10.1001\/jama.290.17.2271"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group: Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler Thromb, 1993; 13: 1291- 1298","DOI":"10.1161\/01.ATV.13.9.1291"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wiegman A, Hutten BA, de Groot E, Rosenberg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA, 2004; 292: 331-337","DOI":"10.1001\/jama.292.3.331"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Boren J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AFH, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjarg-Hansen A, Wiklund O on behalf of for the European Atherosclerosis Society Consensus Panel: Familial hypercholesterolemia in children and adolescents: gaining decade of life by optimizing detection and treatment. Eur Heart J, 2015; 36: 2425-2437","DOI":"10.1093\/eurheartj\/ehv157"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K, Harada-Shiba M, Arai H, Bujo H, Nohara A, Ohta T, Oikawa S, Okada T, Wakatsuki A: Familial Hypercholesterolemia Executive Summary of the Japan Atherosclerosis Society(JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan\u20142012 Version. J Atheroscler Thromb, 2014; 21: 6-10","DOI":"10.5551\/jat.20040"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Katsuren K, Nakamura K, Ohta T: Effect of body mass index Z-score on adverse levels of cardiovascular disease risk factors. Pediatr Int, 2012; 54: 200-204","DOI":"10.1111\/j.1442-200X.2011.03499.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ohshiro T, Shimabukuro T, Sunagawa M, Ohta T: An 11-yearold boy with familial hypercholesterolemia showing multiple xanthomas and advanced atherosclerosis, who responded to lipid-lowering therapy using statin. J Atheroscler Thromb, 2009; 16: 698-701","DOI":"10.5551\/jat.No810"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ohshiro T, Mabuchi H, Ohta T: An 11-year-old boy with familial hypercholesterolemia showing multiple xanthomas and advanced atherosclerosis, who responded to lipidlowering therapy using statin (Letter to Editor). J Atheroscler Thromb, 2010; 17: 1113","DOI":"10.5551\/jat.6676"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Miyagi Y, Harada-Shiba M, Ohta T: Effect of statin therapy in 4-year-old dichromatic and diamniotic twin with familial hypercholesterolrmia showing multiple xanthomas. J Atheroscler Thromb, 2016; 23: 112-117","DOI":"10.5551\/jat.31666"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ohta T, Kiwaki K, Endo F, Umehashi H, Matsuda I: Dyslipidemia in young Japanese children: Its relation to familial hypercholesterolemia and familial combined hyperlipidemia. Pediatr Int, 2002; 44: 602-607","DOI":"10.1046\/j.1442-200X.2002.01635.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Santos RD, Frauches TS, Chacra APM: Cascade Screening in Familial Hypercholesterolemia: Advancing Forward. J Atheroscler Thromb, 2015; 22: 869-880","DOI":"10.5551\/jat.31237"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Fouchier SW, Dallinga-Thie GM, Meijers JC, Zelcer N, Kastelein JJ, Defesche JC, Hovingh GK: Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res, 2014; 115: 552-555","DOI":"10.1161\/CIRCRESAHA.115.304660"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Harada-Shiba M, Takagi A, Miyamoto Y, Tsushima M, Ikeda Y, Yokoyama S, Yamamoto A: Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab, 2003; 88: 2541-2547","DOI":"10.1210\/jc.2002-021487"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tada H, Kawashiri MA, Ikewaki K, Terao Y, Noguchi T, Nakanishi C, Tsuchida M, Takata M, Miwa K, Konno T, Hayashi K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M: Altered metabolism of low-density lipoprotein and very-lowdensity lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet, 2012; 5: 35-41","DOI":"10.1161\/CIRCGENETICS.111.960948"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, Yamagishi M, Kobayashi J, Mabuchi H: The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis, 2010; 210: 166-172","DOI":"10.1016\/j.atherosclerosis.2009.11.018"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Inoue T, Mori M, Tada H, Nakanishi C, Yagi K, Yamagishi M, Ueda K, Takegoshi T, Miyamoto S, Inazu A, Koizumi J, Hokuriku FH Study Group: Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis, 2014; 236: 54-61","DOI":"10.1016\/j.atherosclerosis.2014.06.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) sis, 2014; 236: 54-61 19) Tada H, Kawashiri MA, Takata M, Matsunami K, Imamura A, Matsuyama M, Sawada H, Nunoi H, Konno T, Hayashi K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M: Infantile cases of sitosterolaemia with novel mutations in the ABCG5 gene: Extreme hypercholesterolaemia is exacerbated by breast feeding. JIMD Rep, 2015; 21: 115-122","DOI":"10.1007\/8904_2014_404"},{"key":"20","unstructured":"20) Japan Atherosclerosis Society: Guide for the treatment of dyslipidemia for prevention of atherosclerotic diseases 2013 (in Japanese)"},{"key":"21","unstructured":"21) Ministry of Health, Labour and Welfare: Overview of Dietary Reference Intakes for Japanese (2015), http:\/\/ www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/Overview.pdf"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Committee Report 7-A Treatment A) Lifestyle Modification. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan\u20142012 Version. J Atheroscler Thromb 2013; 20: 835-845","DOI":"10.5551\/jat.18820"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Amemiya S, Dobashi K, Urakami T, Sugihara S, Ohzeki T, Tajima N: Metabolic syndrome in youths. Pediatr Diabetes. 2007; 8 Suppl 9: 48-54","DOI":"10.1111\/j.1399-5448.2007.00332.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Dobashi K: Evaluation of Obesity in School-Age Children. J Atheroscler Thromb, 2016; 23: 32-38","DOI":"10.5551\/jat.29397"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Asayama K, Ozeki T, Sugihara S, Ito K, Okada T, Tamai H, Takaya R, Hanaki K, Murata M: Criteria for medical intervention in obese children: a new definition of 'obesity disease' in Japanese children. Pediatr Int. 2003; 45: 642-646","DOI":"10.1046\/j.1442-200X.2003.01795.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJG, Kastelein JP: Arterial intima media thickness in children heterozygous for familial hypercholesterolaemia. Lancet, 2004; 363: 369-370","DOI":"10.1016\/S0140-6736(04)15467-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Wierzbicki AS, Humphries SE, Minhas R: Familial hypercholesterolaemia: summary of NICE guidance. Br Med J, 2008; 337: 509-510","DOI":"10.1136\/bmj.a1095"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kwiterovich PO Jr: Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab, 2008; 93: 4200-4209 3","DOI":"10.1210\/jc.2008-1270"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li KW, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum S G, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Ware-ham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimaki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar Naveed; HMG-coenzyme A reductase inhibition, type 2 diabetes, and body weight: evidence from genetic analysis and randomised trials. Lancet, 2015; 385: 351-361","DOI":"10.1016\/S0140-6736(14)61183-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Malloy MJ, Kane JP, Kunitake ST, Tun P: Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med, 1987; 107: 616-623","DOI":"10.7326\/0003-4819-107-5-616"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Uauy R, Vega GL, Grundy SM, Bilheimer DM: Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr, 1988; 113: 387-392","DOI":"10.1016\/S0022-3476(88)80289-0"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA: Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 2017; 5: 280-290","DOI":"10.1016\/S2213-8587(17)30044-X"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Nozue T: Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb, 2017; 24: 895-907","DOI":"10.5551\/jat.RV17012"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Yamamoto A, Harada-Shiba M, Kawaguchi A, Oi K, Kubo H, Sakai S, Mikami Y, Imai T, Ito T, Kato H, Endo M, Sato I, Suzuki Y, Hori H: The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis, 2000; 153: 89-98","DOI":"10.1016\/S0021-9150(00)00373-7"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T: Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis, 1983; 48: 157","DOI":"10.1016\/0021-9150(83)90102-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303","DOI":"10.5551\/jat.E610"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Jones DB, Simpson HC, Slaughter P, Lousley S, Carter RD, Cobbe SM, Mann JI: A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. Atherosclerosis, 1984; 53: 1-7","DOI":"10.1016\/0021-9150(84)90099-6"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Buckley MM, Goa KL, Price AH, Brogden RN: Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs, 1989; 37: 761-800","DOI":"10.2165\/00003495-198937060-00002"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H, Shoji T: The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis, 2006; 186: 126-131","DOI":"10.1016\/j.atherosclerosis.2005.06.039"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Taubel J, Sumeray M, Lorch U, McLean A: Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese Subjects. J Atheroscler Thromb, 2016; 23: 606-620","DOI":"10.5551\/jat.30452"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Harada-Shiba M, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Chang Q, Foulds P: Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb, 2017; 24: 402-411","DOI":"10.5551\/jat.38216"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Stefanutti C, Giacomo SD, Vivenzio A, Colloridi V, Bosco G, Berni A, Rabbone I, Cerutti F, Bertolini S: Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr, 2001; 90: 694-701","DOI":"10.1080\/080352501750258793"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Makino H, Harada-Shiba M: Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia: Ther Apher Dial 2003; 7: 397-401","DOI":"10.1046\/j.1526-0968.2003.00073.x"},{"key":"44","unstructured":"44) Mol MJ, Stalenhoef AF: Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis. Neth J Med, 1990; 36: 279-287"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Naito C, Yamamoto A, Saito Y, Muto E, Nishide T, Shinomiya M, Mukai M, Tomono S, Sato T, Yasuda K, Yamauchi T, Mabuchi H, Kobayashi J, Ueda H, Nonaka K, Wada N, Yamasak S, Ono T, Yoshimura A, Harada M, Nakamura H, Kondo K, Ageta M, Matsui T, Mayuyama H, Fukuo Y, Matsuzawa Y, Irie Y, Kon T, Endo M, Yuasa Y, Takahashi Y, Koda Y, Hara Y, Kikkawa T, Oikawa S, Ito H, Homma Y, Iino Y, Takahashi Y, Ito H, Teramoto T, Takahashi K, Mimori A, Takada H, Suzuki M, Kawanishi H, Yashiro A, Tazaki H, Segawa J, Sugano, Kawashima T, Matsushima T, Nakajima Y: Long term effect of LDL apheresis in Japan. LDL Apheresis Study Group. Biomater Artif Cells Immobilization Biotechnol, 1991; 19: 19-26","DOI":"10.3109\/10731199109117812"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M: Apheresis technology for prevention and regression of atherosclerosis. Ther Apher 2001; 5: 221-225","DOI":"10.1046\/j.1526-0968.2001.00328.x"},{"key":"47","unstructured":"47) http:\/\/www.shouman.jp\/ (in Japanese)"},{"key":"48","unstructured":"48) http:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000084783.html (in Japanese)"},{"key":"49","unstructured":"49) Youngblom E, Joshua W Knowles JW: Familial hypercholesterolemia. Gene Reviews. [Internet] http:\/\/www.ncbi. nlm.nih. gov\/books\/NBK174884\/ (Mar 8th 2016)"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/6\/25_CR002\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T09:07:28Z","timestamp":1570698448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/6\/25_CR002\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.cr002","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}